Tavneos controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2026
France recalls Tavneos batches after deaths linked in Japan
Recall announced
France's medicine safety agency ANSM said that the recall of all Tavneos batches available in France would begin on August 19. The drug is made by U.S. biotech firm Amgen and sold by partner companies worldwide. It was linked to 20 deaths in Japan. The European Commission had revoked the drug's marketing authorisation earlier in the month.
France's medicine safety agency ANSM said the recall of all Tavneos batches available in France would begin on August 19, after the drug, made by U.S. biotech firm Amgen and sold by partner companies worldwide, was linked to 20 deaths in Japan. The European Commission had revoked the drug's marketing authorisation earlier in the month.
Company response
Recall — France's medicine safety agency ANSM
"The recall of all batches available in France will begin on August 19," France's medicine safety agency ANSM said in a statement.
Source excerpt
The European Commission revoked the drug's marketing authorisation earlier this month because "the benefits are no longer proven to outweigh its risks".
Kissei Pharmaceutical, which sells the drug in Japan, said in May that 20 deaths had been reported among people using the it since 2022.
A drug called Tavneos used to treat rare autoimmune diseases will be pulled from the shelves in France, the country's medicine watchdog said Wednesday, after it was linked to 20 deaths in Japan.